Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Hepatocellular carcinoma: clinical frontiers and perspectives.

Bruix J, Gores GJ, Mazzaferro V.

Gut. 2014 May;63(5):844-55. doi: 10.1136/gutjnl-2013-306627. Epub 2014 Feb 14. Review.

2.

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.

Abdel-Rahman OM, Elsayed Z.

Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2. Review.

PMID:
26905230
3.

Hepatocellular carcinoma.

Daoudaki M, Fouzas I.

Wien Med Wochenschr. 2014 Nov;164(21-22):450-5. doi: 10.1007/s10354-014-0296-7. Epub 2014 Sep 3. Review. Erratum in: Wien Med Wochenschr. 2014 Nov;164(21-22):497.

PMID:
25182146
4.

Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.

Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group..

Trials. 2014 Dec 3;15:474. doi: 10.1186/1745-6215-15-474.

5.

Multimodal approaches to the treatment of hepatocellular carcinoma.

Cabibbo G, Latteri F, Antonucci M, Craxì A.

Nat Clin Pract Gastroenterol Hepatol. 2009 Mar;6(3):159-69. doi: 10.1038/ncpgasthep1357. Epub 2009 Feb 3. Review.

PMID:
19190599
6.

Hepatocellular carcinoma review: current treatment, and evidence-based medicine.

Raza A, Sood GK.

World J Gastroenterol. 2014 Apr 21;20(15):4115-27. doi: 10.3748/wjg.v20.i15.4115. Review.

7.

Challenges of advanced hepatocellular carcinoma.

Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F.

World J Gastroenterol. 2016 Sep 14;22(34):7645-59. doi: 10.3748/wjg.v22.i34.7645. Review.

8.

Managing localized unresectable hepatocellular carcinoma.

Narang-Master J, Rizzolo D.

JAAPA. 2015 Jan;28(1):27-34. doi: 10.1097/01.JAA.0000458854.46279.d8. Review.

PMID:
25486501
9.

Newer treatments for advanced hepatocellular carcinoma.

Song MJ, Bae SH.

Korean J Intern Med. 2014 Mar;29(2):149-55. doi: 10.3904/kjim.2014.29.2.149. Epub 2014 Feb 27. Review.

10.

[Hepatocellular Carcinoma: therapeutic options 2015].

Schultheiß M, Bettinger D, Neeff HP, Brunner TB, Thimme R.

Dtsch Med Wochenschr. 2015 Jul;140(14):1063-8. doi: 10.1055/s-0041-102333. Epub 2015 Jul 16. German.

PMID:
26182255
11.

Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.

Gish RG, Finn RS, Marrero JA.

Clin Adv Hematol Oncol. 2013 Apr;11 Suppl 5:1-22; quiz 2 p following p22.

PMID:
23881427
12.

Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.

Kan X, Jing Y, Wan QY, Pan JC, Han M, Yang Y, Zhu M, Wang Q, Liu KH.

Eur Rev Med Pharmacol Sci. 2015;19(2):247-55.

13.

Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival.

Nagai S, Mangus RS, Kubal CA, Ekser B, Fridell JA, Klingler KR, Maluccio MA, Tector AJ.

Clin Transplant. 2015 Dec;29(12):1156-63. doi: 10.1111/ctr.12644. Epub 2015 Nov 14.

PMID:
26458066
14.

Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.

Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S, Bolondi L, Bernardi M, Trevisani F; BLOG (Bologna Liver Oncology Group)..

Liver Int. 2015 Mar;35(3):1036-47. doi: 10.1111/liv.12574. Epub 2014 May 20.

PMID:
24750853
15.

Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.

Ramanathan R, Sharma A, Lee DD, Behnke M, Bornstein K, Stravitz RT, Sydnor M, Fulcher A, Cotterell A, Posner MP, Fisher RA.

Transplantation. 2014 Jul 15;98(1):100-6. doi: 10.1097/01.TP.0000441090.39840.b0.

16.

[Therapy of hepatocellular carcinoma].

Wörns MA, Klöckner R, Weinmann A, Galle PR.

Internist (Berl). 2014 Jan;55(1):23-4, 26-30. doi: 10.1007/s00108-013-3318-4. German.

PMID:
24240604
17.

Hepatocellular carcinoma.

Forner A, Llovet JM, Bruix J.

Lancet. 2012 Mar 31;379(9822):1245-55. doi: 10.1016/S0140-6736(11)61347-0. Epub 2012 Feb 20. Review.

PMID:
22353262
18.

Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).

Schmidt L, op den Winkel M, Fischer K, Straub G, Rauch B, Paprottka PM, Göke B, Kolligs FT.

Digestion. 2014;90(4):219-28. doi: 10.1159/000367686. Epub 2014 Dec 9.

PMID:
25502689
19.

Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.

Feng X, Xu R, Du X, Dou K, Qin X, Xu J, Jia W, Wang Z, Zhao H, Yang S, Guo C, Liu T, Ma K.

Am J Gastroenterol. 2014 Dec;109(12):1891-9. doi: 10.1038/ajg.2014.343. Epub 2014 Nov 18.

PMID:
25403366
20.

Hepatocellular carcinoma: options for diagnosing and managing a deadly disease.

Murali AR, Romero-Marrero C, Aucejo F, Menon KV.

Cleve Clin J Med. 2013 Oct;80(10):645-53. doi: 10.3949/ccjm.80a.12163. Review.

Supplemental Content

Support Center